(Q37132710)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence--based clinical perspective (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

0 references

5

Silvano Adami

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Piet P Geusens

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Christian H Roux

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

David M Reid

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Willem F Lems

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Jonathan D Adachi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Philip N Sambrook

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Kenneth G Saag

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Nancy E Lane

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Marc C Hochberg

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

8 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Rheumatology

5 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

240-248

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

5 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNCPRHEUM0773

Calcium and vitamin D for corticosteroid-induced osteoporosis

21 January 2018

1 reference

12 December 2020

Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group

1 reference

12 December 2020

Severely suppressed bone turnover: a potential complication of alendronate therapy

1 reference

12 December 2020

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

1 reference

12 December 2020

Mechanisms of anabolic therapies for osteoporosis

1 reference

12 December 2020

Osteonecrosis of the jaw: more research needed

1 reference

12 December 2020

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

1 reference

12 December 2020

Risk of new clinical fractures within 2 years following a fracture

1 reference

12 December 2020

Risk of Subsequent Fracture After Low-Trauma Fracture in Men and Women

1 reference

12 December 2020

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study

1 reference

12 December 2020

Yearly zoledronic acid in postmenopausal osteoporosis

1 reference

12 December 2020

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Review of guidelines for testing and treatment of osteoporosis

1 reference

12 December 2020

Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study

1 reference

12 December 2020

1 reference

12 December 2020

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older

1 reference

12 December 2020

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

1 reference

12 December 2020

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

1 reference

12 December 2020

Bisphosphonates: from bench to bedside

1 reference

12 December 2020

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

12 December 2020

Novel targets and therapeutics for bone loss.

1 reference

12 December 2020

Recommendations for zoledronic acid treatment of patients with bone metastases

1 reference

12 December 2020

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

1 reference

12 December 2020

Data extraction errors in meta-analyses that use standardized mean differences

1 reference

12 December 2020

Alendronate and atrial fibrillation.

1 reference

12 December 2020

Determinants of skeletal fragility

1 reference

12 December 2020

How to select the doses of vitamin D in the management of osteoporosis

1 reference

12 December 2020

Efficacy of risedronate on clinical vertebral fractures within six months.

1 reference

12 December 2020

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.

1 reference

12 December 2020

Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling

1 reference

12 December 2020

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

1 reference

12 December 2020

The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial

1 reference

12 December 2020

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

1 reference

12 December 2020

Barriers to effective management of osteoporosis in moderate and minimal trauma fractures: a prospective study

1 reference

12 December 2020

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial

1 reference

12 December 2020

Assessment of non-vertebral fracture risk in postmenopausal women

1 reference

12 December 2020

Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures

1 reference

12 December 2020

Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies

1 reference

12 December 2020

Assessment of fracture risk

1 reference

12 December 2020

Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose

1 reference

12 December 2020

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

1 reference

12 December 2020

Diagnosis of vertebral fractures by vertebral fracture assessment.

1 reference

12 December 2020

Genetic regulation of bone mass and susceptibility to osteoporosis

1 reference

12 December 2020

Risk factors for fractures of the distal forearm and proximal humerus. The Study of Osteoporotic Fractures Research Group

1 reference

12 December 2020

Bone and Fall-Related Fracture Risks in Women and Men with a Recent Clinical Fracture

1 reference

12 December 2020

Zoledronic acid and clinical fractures and mortality after hip fracture

1 reference

12 December 2020

Clinical practice. Osteopenia.

1 reference

12 December 2020

Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials

1 reference

12 December 2020

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial

1 reference

12 December 2020

Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women

1 reference

12 December 2020

Parathyroid hormone as an anabolic skeletal therapy

1 reference

12 December 2020

7: Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture.

1 reference

12 December 2020

Daily and cyclic parathyroid hormone in women receiving alendronate

1 reference

12 December 2020

Transmission of human herpesvirus 8 by blood transfusion

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNCPRHEUM0773

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NCPRHEUM0773

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398411%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

PubMed publication ID

18398411

1 reference